Treatment of Tuberculous Lymphadenitis
First-Line Treatment Regimen
- The American Thoracic Society recommends a 6-month regimen consisting of rifampin, isoniazid, pyrazinamide, and ethambutol for the initial 2 months, followed by rifampin and isoniazid for an additional 4 months, for the treatment of tuberculous lymphadenitis 1, 2
- The European Respiratory Society recommends the 2HRZE/4HR regimen (2 months of isoniazid, rifampin, pyrazinamide, and ethambutol, followed by 4 months of isoniazid and rifampin) for tuberculous lymphadenitis, which has been shown to be effective for peripheral lymph node tuberculosis 1, 2
- Standard dosing for adults includes:
Treatment Considerations
- Ethambutol may be omitted in patients with a low risk of isoniazid resistance (isoniazid resistance rate <4%) and in previously untreated patients who are HIV-negative 1, 2
- In cases where positive culture for M. tuberculosis has been obtained but susceptibility results are pending after two months, treatment including pyrazinamide and ethambutol should be continued until full susceptibility is confirmed 1
- Directly observed therapy (DOT) is recommended to ensure treatment adherence, particularly for intermittent regimens 2
Special Populations
- For HIV-infected patients with tuberculous lymphadenitis, the Centers for Disease Control and Prevention recommends the same 6-month regimen, but if isoniazid is chosen as part of the regimen, a 9-month duration is preferred 3, 4
- For children, dosing should be weight-based, with isoniazid at 10-15 mg/kg (up to 300 mg) daily 1
Management of Drug Resistance
- For isoniazid-resistant tuberculous lymphadenitis, the American Thoracic Society recommends adding a later-generation fluoroquinolone to a 6-month regimen of daily rifampin, ethambutol, and pyrazinamide 5
Monitoring and Follow-up
- Patients should be monitored monthly for treatment response and adverse effects, as recommended by the Centers for Disease Control and Prevention 6